Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-Remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)UnknownNCT01407211
What this trial is testing

Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Tehran University of Medical Sciences 30
Not applicableStudy completedNCT03653585
What this trial is testing

Cortical Lesions in Patients With Multiple Sclerosis

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Danish Research Centre for Magnetic Resonance 80
Testing effectiveness (Phase 2)Study completedNCT00879658
What this trial is testing

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Novartis Pharmaceuticals 297
Not applicableStudy completedNCT01142453
What this trial is testing

An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany 231
Not applicableStudy completedNCT06915272
What this trial is testing

Effects of Sailing and Cooing in the Quality of Life of Multiple Sclerosis Individuals

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remitting
University of Thessaly 45
Not applicableUnknownNCT04885894
What this trial is testing

An Examination of Cognitive Fatigue Using Functional Neuroimaging

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Kessler Foundation 60
Not applicableLooking for participantsNCT07758270
What this trial is testing

Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remitting
Washington University School of Medicine 15
Large-scale testing (Phase 3)Study completedNCT02283853
What this trial is testing

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 156
Early research (Phase 1)UnknownNCT02903537
What this trial is testing

Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic Progressive
Fundació Institut Germans Trias i Pujol 16
Large-scale testing (Phase 3)Study completedNCT02637856
What this trial is testing

Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Genentech, Inc. 608
Testing effectiveness (Phase 2)Study completedNCT00071838
What this trial is testing

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
National Institute of Neurological Disorders and Stroke (NINDS) 16
Not applicableUnknownNCT06435962
What this trial is testing

Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Assiut University 100
Early research (Phase 1)Study completedNCT02310048
What this trial is testing

Comparative Oral Bioavailability Study of MT-1303

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Tanabe Pharma Corporation 34
Not applicableLooking for participantsNCT06567197
What this trial is testing

Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Amsterdam UMC, location VUmc 24
Testing effectiveness (Phase 2)Ended earlyNCT06220669
What this trial is testing

LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Eli Lilly and Company 63
Not applicableStudy completedNCT03975413
What this trial is testing

Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Rush University Medical Center 1
Not applicableStudy completedNCT01518660
What this trial is testing

Multiple Sclerosis and Progressive Resistance Training

Who this might be right for
Multiple Sclerosis (Relapsing Remitting)
University of Aarhus 35
Large-scale testing (Phase 3)Study completedNCT02525874
What this trial is testing

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis
Biogen 218
Not applicableStudy completedNCT02159573
What this trial is testing

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 530
Post-approval studies (Phase 4)Study completedNCT02720107
What this trial is testing

Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Novartis Pharmaceuticals 133
Next Page